When was AxoGen founded?

AxoGen was founded in 2002 and raised its 1st funding round 5 years after it was founded.

Where is AxoGen located?

AxoGen is headquartered in Alachua, United States.

How many employees does AxoGen have?

As of Aug 31, 2026, the latest employee count at AxoGen is 635.

Is AxoGen a funded company?

AxoGen is a funded company, having raised a total of $62.4M across 13 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Dec 04, 2007.

When was the latest funding round of AxoGen?

AxoGen's latest funding was a $***** Grant (prize money) round on Oct 15, 2025, with participation from 1 investor.

What is the annual revenue of AxoGen?

Annual revenue of AxoGen is between $100M and $500M as on Dec 31, 2025

Where does AxoGen rank among its competitors?

AxoGen ranks 2nd amongst 49 active competitors, of which 13 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was TYBR Health, which secured $30M in Jul, 2026.

Who are the top competitors of AxoGen?

AxoGen's top competitors include Humacyte, CUTISS and Acera Surgical. Among them, TYBR Health secured the most recent funding round in July, 2026.

AxoGen - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of therapies for the repair of peripheral nerve injuries. The flagship product is the AVANCE Nerve Graft, a human allograft nerve for treating damaged peripheral nerves. Other products include AxoGuard Nerve Connector and Protector (extracellular matrices), and AxoTouch Two-Point Discriminator tool, a set of two aluminum discs to measure sensation after a nerve injury.

Website: www.axogeninc.com/
Social

Key Metrics

Founded Year

2002

Location

Alachua, United States

Stage

Public

Total Funding

$62.4M in 13 rounds

Latest Funding Round

Grant (prize money), Oct 15, 2025, $*****

Investors

Oberland Capital & 11 more

Ranked

2^nd among 49 active competitors

Annual Revenue

$100M - $500M as on Dec 31, 2025

Employee Count

635 as on Aug 31, 2026

Investment & Acquisitions

BioCircuit & 1 more

Similar Companies

Humacyte & 56 more

Exit Details

Public

View AxoGen's full profile

AxoGen is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Axogen, Inc. CIN: 805928 , United States, Active		$100M - $500M (As on Dec 31, 2025)	-	-
Axogen, Inc. CIN: 41-13018 , United States, Active	Jan 01, 1987	-	428 (As on Dec 31, 2023)	-
Axogen Corporation CIN: 550805988 , United States, Active	Jun 12, 2006	-	448 (As on Dec 31, 2024)	-

AxoGen got listed on Dec 19, 1986.

Click here to take a look at AxoGen's IPO in detail

AxoGen has raised a total funding of $62.4M over 13 rounds. Its first funding round was on Dec 04, 2007. Its latest funding round was a Grant (prize money) round on Oct 15, 2025 for $*****. 1 investor participated in its latest round. AxoGen has 12 institutional investors.

Here is the list of recent funding rounds of AxoGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 15, 2025	4519182	Grant (prize money)	4090824	1582185	4482738	5686991
Oct 26, 2016	8191897	Conventional Debt	6073823	6963975	7487311	6520919
Aug 26, 2015	5762283	Series D	9148730	3948378	1920454	EW Healthcare Partners

Access funding benchmarks and valuations. Sign up today!

View details of AxoGen's funding rounds and investors

AxoGen's employee count trend

AxoGen has 635 employees as of Aug 26. Here is AxoGen's employee count trend over the years:

Uncover AxoGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AxoGen include Humacyte, CUTISS and Acera Surgical. Here is the list of Top 10 competitors of AxoGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Humacyte 2004, Durham (United States), Public	Provider of human tissue-based products for vascular disease	$425M	Access Industries, Fresenius Medical Care ... & 15 others	66/100
2nd	AxoGen 2002, Alachua (United States), Public	Developer of therapies for the repair of peripheral nerve injuries	$62.4M	Oberland Capital, Cardinal Partners & 10 others	65/100
3rd	CUTISS 2017, Zurich (Switzerland), Series C	Company developing personalized skin tissue therapeutics for skin defect treatments	$157M	Cherry Bay Capital Group, Rode Kruis Ziekenhuis ... & 15 others	63/100
4th	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	57/100
5th	Tulavi Nerve Therapeutics 2020, Mountain View (United States), Series A	Developer of the therapeutic device to treat neurally mediated diseases	$11.5M	Ascension Ventures, AMED Ventures & 1 others	56/100
6th	TYBR Health 2020, Houston (United States), Series A	Provider of regenrative medicine for post surgical scarring	$38.4M	Vensana Capital, Y Combinator & 4 others	56/100
7th	BioCircuit 2016, Atlanta (United States), Acquired	Developer of non-invasive electrophysiology devices to monitor peripheral nerves	$13.6M	Masters Capital Management, GRA Venture Fund ... & 4 others	55/100
8th	Tissue Regenix 2006, Swillington (United Kingdom), Public	Developer of regenerative medical devices by using cell technology	-	Harwood Capital, IP Group & 2 others	53/100
9th	Epibone 2013, Brooklyn (United States), Series B	Developer of patient‑specific bone and cartilage grafts	$48.6M	Kendall Capital Partners, MBX Capital & 25 others	51/100
10th	Aroa Biosurgery 2008, Mangere (New Zealand), Public	Developer of medical and surgical products for soft tissue reconstruction	-	Alium Capital, Cure Kids Ventures & 2 others	51/100